valemetostat   Click here for help

GtoPdb Ligand ID: 12282

Synonyms: (R)-OR-S2 [2] | DS-3201 | DS3201 | Ezharmia®
Approved drug
valemetostat is an approved drug (Japan (2022))
Compound class: Synthetic organic
Comment: Valemetostat (DS-3201) is an orally bioavailable, S-adenosylmethionine (SAM)-competitive inhibitor of the histone methyltransferases enhancer of zeste homologue 1 and 2 (EZH1/EZH2) [2] that are responsible for tri-methylation of lysine 27 on histone H3 (H3K27me3) by the polycomb repressive complex 2 (PRC2). H3K27me3 is an epigenetic modification that represses transcription of tumour suppressor and cell differentiation genes). Valemetostat was developed to target cancers with ongogenic defects that are driven by excessive activity of EZH1 and EZH2 [4-5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 83.66
Molecular weight 487.22
XLogP 5.25
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN(C1CCC(CC1)[C@@]1(C)Oc2c(O1)c(C)c(cc2Cl)C(=O)NCc1c(C)cc([nH]c1=O)C)C
Isomeric SMILES Cc1cc(c(c(=O)[nH]1)CNC(=O)c1cc(c2c(c1C)O[C@@](O2)(C)C1CCC(CC1)N(C)C)Cl)C
InChI InChI=1S/C26H34ClN3O4/c1-14-11-15(2)29-25(32)20(14)13-28-24(31)19-12-21(27)23-22(16(19)3)33-26(4,34-23)17-7-9-18(10-8-17)30(5)6/h11-12,17-18H,7-10,13H2,1-6H3,(H,28,31)(H,29,32)/t17?,18?,26-/m1/s1
InChI Key SSDRNUPMYCFXGM-ZZHSESOFSA-N
No information available.
Summary of Clinical Use Click here for help
Valemetostat (as the tosilate salt) was first approved as a treatment for aggressive adult T-cell leukemia/lymphoma (ATL; a subtype of non-Hodgkin lymphoma) in Japan in September 2022 [1]. It will also be evaluated for efficacy against advanced/metastatic solid tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04102150 Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma Phase 2 Interventional Daiichi Sankyo, Inc. 3
NCT05633979 Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer Phase 1 Interventional M.D. Anderson Cancer Center
NCT04388852 DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Phase 1 Interventional M.D. Anderson Cancer Center